• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Clin Microbiol Infect . SARS-CoV-2 new infections among health care workers after the first dose of the BNT162b2 mRNA Covid-19 vaccine. a hospital

tetano

Editor, Senior Moderator
Clin Microbiol Infect


. 2021 Jun 28;S1198-743X(21)00347-5.
doi: 10.1016/j.cmi.2021.06.026. Online ahead of print.
SARS-CoV-2 new infections among health care workers after the first dose of the BNT162b2 mRNA Covid-19 vaccine. a hospital wide cohort study


Carlos Guijarro[SUP] 1 [/SUP], Isabel Galán[SUP] 2 [/SUP], Diana Martínez-Ponce[SUP] 2 [/SUP], Elia Pérez-Fernández[SUP] 3 [/SUP], Maria José Goyanes[SUP] 4 [/SUP], Virgilio Castilla[SUP] 5 [/SUP], María Velasco[SUP] 6 [/SUP]



Affiliations

Abstract

Objectives: To evaluate the effect of mRNA SARS-Cov-2 vaccination on the incidence of new SARS-CoV-2 infections in health care workers (HCW).
Methods: The evolution of the incident rate of microbiologically confirmed SARS-CoV-2 infection in a cohort of 2590 HCW after BNT162b2 mRNA SARS-CoV-2 vaccination, as compared to the rate in the community (n=170513) was evaluated by mixed Poisson regression models.
Results: A total of 1820 HCW (70,3% of total) received the first dose of the BNT162b2 mRNA vaccine between January 10-16, 2021), and 296 (11,4%) the following week. All of them completed vaccination 3 weeks later. Incidence rates of SARS-CoV-2 infection after the first dose of mRNA SARS-CoV-2 vaccine declined by 71% (Incidence Rate Ratio (IRR) 0.286, 95% confidence interval (CI) 0.174-0.468, p< 0.001) and by 97% (IRR 0.03 95% CI 0.013-0.068, p<0.001) after the second dose as compared to the perivaccine time. SARS-CoV-2 incidence rates in the community (with a negligible vaccination rate) had a much lower decline: 2% (IRR 0.984; 95% CI 0.943-1.028; p = 0.47) and 61% (IRR 0.390, 95% CI 0.375-0.406; p<.001) for equivalent periods. Adjusting for the decline in the community, the reduction in the incident rates among HCW were 73% (IRR 0.272; 95% CI 0.164-0.451 p<0.001) after the first dose of the vaccine and 92 % (IRR 0.176, 95% CI 0.033-0.174; p<0.001) after the second dose.
Conclusions: mRNA SARS-CoV-2 vaccination is associated with a dramatic decline in new SARS-CoV-2 infection among HCW, even before the administration of the second dose of the vaccine.

Keywords: COVID-19; SARS-CoV-2; coronavirus; health care workers; incidence; infection; mRNA vaccine; vaccine.
 
Back
Top Bottom